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Abstract
Aim: To verify if patients with cervical neoplasia produce mediators that reduce leukocyte function.
Methods: Control neutrophils incubated with normal serum or serum from pre-invasive or invasive neoplasia patients were assayed 
for chemotaxis. Mediators were assayed in serum and in leukocyte supernatants. Experiments were also performed in random patients 
after surgery.
Results: Neutrophils incubated with patient sera, but not normal sera, failed to migrate towards the chemoattractants. In   invasive 
  neoplasia compared to controls, IL-6 and IL-8, and IL-10 and TNF-α were elevated in serum and in neutrophil supernatants, 
  respectively. Nitrite levels were elevated in mononuclear cell supernatants from patients than controls. After surgery, serum cytokine 
levels were reduced, mainly in pre-invasive patients. Neutrophils treated with serum from pre-invasive patients undergone surgery 
had restored migration.
Conclusion: Patients with cervical neoplasia produce mediators, predominantly induced by tumor cells, able to impair the inflammatory 
response at very early stages of disease.
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Introduction
Macrophages and lymphocytes have been the pre-
dominant  focus  of  studies  into  the  mechanisms 
involved in the elimination of tumor cells, but neu-
trophils also possess anti-tumor activity through the 
induction of apoptosis-inducing genes.1 In addition, 
these cells contain reactive oxygen species and pro-
teinases that are capable of modifying tumor growth 
and   invasiveness.2 Pre-clinical studies evaluating the 
treatment of advanced rectal carcinoma have demon-
strated that granulocytes are the most effective cell 
population.3 The anti-tumor activity of alemtuzumab, 
a monoclonal antibody approved for the treatment 
of  B-cell  chronic  lymphocytic  leukemia,  has  been 
shown to be mediated by neutrophils, since increas-
ing the number of circulating neutrophils enhanced 
the anti-tumor activity of the antibody.4
Patients  with  cancer  may  present  alterations 
in    leukocyte  function.  Neutrophils  obtained  from 
patients with colorectal carcinoma had reduced phago-
cytic activity upon diagnosis compared to   controls.5 
In   addition, patients with gynecologic cancer, includ-
ing  cervical  cancer,  had  reduced  production  of 
  superoxides at the initial stages that markedly evolved 
with the disease.6 In epithelial ovarian cancer patients, 
a defect in the anti-tumor function of macrophages 
has  been  reported.7  Multiple  lineages  of  tumors, 
including breast cancer, colon cancer and melanoma, 
exhibit an   interruption in the functional maturation of 
natural-killer-cells during tumor growth.8
The mechanisms involved in the inhibition of leu-
kocyte function in cancer patients may in part, be due 
to the presence of circulating factors.9–11   Circulating 
cytokines and chemokines reduce neutrophil   adhesion 
to  endothelial  cells  through  the  activation  of  the 
  inducible  nitric  oxide  synthase,  which  results  in  a 
reduction of neutrophil migration to the site of infec-
tion in models of sepsis.12 Moreover, plasma concen-
tration of cytokines and nitric oxide (NO) is increased 
in human sepsis.13
Previously, we had shown that a defect in neutro-
phil migration was associated with cancer progres-
sion in cervical neoplasia, which is the second most 
common cancer in women worldwide. A reduction 
in the capacity of neutrophil migration was evident 
in patients with invasive cervical cancer compared 
with patients at early stages of the disease and with 
controls. In addition, surgical elimination of tumors 
in patients with pre-invasive neoplasia resulted in an 
increase in neutrophil and mononuclear cell migra-
tion, suggesting that tumor cells may produce inhibi-
tory soluble factors of leukocyte migration.14,15
Based  on  these  observations,  we  hypothesized 
that patients with uterine cervical neoplasia produce 
circulating factors with inhibitory effect on leukocyte 
function, apart from pre-invasive stage. To address this 
question, we evaluated whether there are alterations 
in the migratory capacity of normal blood neutrophils 
treated with sera from patients with cervical neoplasia. 
In  addition,  we  quantified  the  systemic  levels  of 
mediators that may be involved in the inhibition of 
neutrophil  migration  in  those  patients.  Finally,  in 
order to confirm these findings, we assessed the same 
parameters after surgical treatment.
patients and Methods
Patients
Women attending the Outpatient Gynecologic Ser-
vice of the Federal University of Triângulo Mineiro 
(UFTM) who had been diagnosed with cervical neo-
plasia were considered for this study. Patients were not 
included if they had previously received treatment or 
were under current use with   immunosuppressors. The 
study protocol was approved by the UFTM Human 
Subject Use Committee and written informed consent 
was obtained from each patient.
Patients  without  clinical  and  cytological  findings 
were considered normal subjects (controls). The final 
cytological  and  anatomopathological  diagnosis  fol-
lowed  the  International  Federation  of  Gynaecology 
and  Obstetrics  (FIGO)  classification.  Accordingly, 
patients were diagnosed as having cervical intraepi-
thelial neoplasia (CIN) grade 3 (pre-invasive neoplasia 
group) or invasive carcinoma (stage IB1 to IVB, inva-
sive group). Randomly selected patients within the pre-
invasive or invasive groups were treated by cold knife 
conization or Wherteim-Meigs surgery, respectively, 
and re-  evaluated for the inhibitory effect of serum on 
neutrophil migration and for the production of media-
tors approximately 30 to 60 d after treatment.
Blood collection
Peripheral  venous  blood  was  collected  from 
the  controls  and  all  patients  upon  diagnosis  and 
then  in  randomly  selected  patients  from  the  pre-
  invasive or invasive groups on follow-up 30 to 60 d Circulating mediators inhibit the neutrophil migration in cervical neoplasia patients
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after   treatment. One 5 mL sample was collected with 
  heparine (100 IU/mL) for purification of leukocytes 
and one 5 mL sample was collected without an anti-
coagulant for assessment of cytokines and NO levels. 
The blood was centrifuged at 180 × g for 15 min and 
the sera was stored at −70 °C for future assessment.
Isolation of neutrophils  
and mononuclear cells
Blood  neutrophils  and  mononuclear  cells  from 
patients with cervical neoplasia or healthy volunteers 
were isolated using a Histopaque gradient.   Viable cells 
(greater than 95% as determined by trypan blue exclu-
sion) were washed three times with RPMI medium 
(Sigma Chemical, St. Louis, MO) with centrifugation 
at 180 × g for 10 min after each wash, and then resus-
pended in RPMI for cell culture or in RPMI contain-
ing 0.01% bovine serum albumin   (RPMI-BSA) for 
the neutrophil chemotaxis assay.
Pretreatment of healthy neutrophils  
with patient sera
Healthy neutrophils were pre-incubated for 30 min at 
37 °C and 5% CO2 with sera (diluted to 0.5% to 50% v/v 
in RPMI-BSA) obtained from normal donors or with sera 
from patients from the pre-invasive or invasive groups. 
In a set of experiments, control neutrophils were also 
incubated with sera obtained from pre-  invasive patients 
after surgical treatment. After incubation, the neutro-
phils were assayed for chemotaxis.
neutrophil migration assay
Chemotaxis  was  assayed  in  48-well  microchemot-
axis chambers (Neuro Probe, Cabin John, MD, USA) 
containing  5-µm  PVP-free  polycarbonate    filters. 
Briefly, 28 µL of the chemoattractants (10−7 M, Sigma) 
N-  formyl-L-methionyl-L-leucyl-L-phenylalanine 
(fMLP), LTB4, or IL-8 were diluted in RPMI-BSA 
and added to individual bottom compartments of the 
chamber. RPMI medium alone was used as a control 
for  random  migration.  Fifty  µL  of  the  neutrophils 
(106 cells/mL) that were previously treated with con-
trol or patient sera was added to the top   compartment. 
The chamber was incubated for 1 h at 37 °C and 5% 
CO2 and then the filter was removed, fixed and stained 
with the Hema 3 Stain set (Biochemical Sciences, 
Bridgeport, NJ). The number of neutrophils that had 
migrated to the lower side of the filter was counted 
(100×  objective)  in  four  randomly  selected  fields. 
Each sample was assayed in triplicate. The results 
were expressed as the absolute number of neutrophils 
per field.
Supernatants obtained  
from cultured leukocytes
Cultured  neutrophils  and  mononuclear  cells 
(106 cells/mL) obtained from the controls and ran-
domly  selected  patients  before  and  after  treatment 
were  stimulated  with  endotoxin  (1  µg/mL  of  LPS 
from E.coli) and incubated at 37 °C and 5% CO2 for 
24 h (neutrophils) or 48 h (mononuclear cells). The 
cells were then centrifuged at 180 × g for 10 min 
and the supernatants were stored at −70 °C for future 
cytokine and nitrite determination.
Determination of serum nO metabolites 
and nitrite in culture supernatants
The  nitrate  concentration  in  serum  samples  from 
controls and patients with cervical neoplasia were 
assayed by enzymatically reducing nitrate. Briefly, 
50  µL  of  samples  were  incubated  with  the  same 
  volume of reductase buffer (0.1 M potassium phos-
phate with 1 mM nicotinamide adenine dinucleotide, 
and 4 units of nitrate reductase/mL) for 20 h at 37 °C. 
A standard nitrate curve was obtained by incubating 
sodium  nitrate  (10–200  µM)  with  the  buffer. The 
total amount of nitrite as well as the amount of nitrite 
in  the  culture  supernatants  was  then  determined 
using the Griess method.16 The samples were incu-
bated with the same volume of Griess reagent (1% 
sulphanilamide and 0.1% naphthylethylenediamine 
  dihydrochloride in 5% phosphoric acid). The absor-
bance at 550 nm was determined by using a multi-
well plate reader. The results were reported as the 
concentration of nitrate plus nitrite (µM NO3 + NO2) 
for  serum  samples  or  concentration  of  nitrite  for 
supernatants.
Cytokine measurements
The concentrations of cytokines in the blood samples 
and in samples obtained from leukocyte supernatants 
were  determined  by  ELISA.  Briefly,  flat-  bottomed 
96-well microtiter plates were coated with an anti-
  cytokine  antibody  (50  µL/well)  diluted  in  coating 
  buffer (150 pg/mL for IL-6, 100 pg/mL for IL-8 or Micheli et al
236  Clinical Medicine Insights: Oncology 2012:6
500  pg/mL  for  IL-10  and  TNF-α)  and  incubated 
  overnight.  The  plates  were  then  washed  and  non-
  specific  binding  was  blocked  with  1%  BSA  for 
120 min at 37 °C. Non-diluted samples and standards 
were  loaded  onto  the  plates.  Recombinant  human 
TNF-α, IL-6, IL-8 and IL-10 standard curves were 
used to calculate the cytokine levels. The plates were 
thoroughly washed and then incubated with the appro-
priate biotinylated monoclonal anti-cytokine antibody 
for 1 h. The plates were washed, incubated with avidin 
peroxidase (diluted 1:5000) for 30 min and washed 
again. The substrate (0.4 mg of o-  phenylenediamine 
dihydrochloride (Sigma, St. Louis, MO, USA) and 
0.4 µL of hydrogen peroxide (Merck, Rio de Janeiro, 
RJ, Brazil) in 1 mL of substrate buffer) was added and 
the reaction was stopped with 1 M H2SO4. The optical 
density was measured on a plate reader at 490 nm. 
The results were expressed as pg of cytokine per mL 
and the optical density of the samples was compared 
to the standard curves.
Statistical analysis
Data were analyzed using SigmaStat 2.03 software. 
Differences between two unpaired groups were tested 
using Student t-test or Mann-Whitney, according to 
the  distribution.  For  multiple  comparisons,  either 
the analysis of variance (ANOVA) followed by the 
Tukey test, or the Kruskal-Wallis followed by Dunn 
were performed, according to normal or non-normal 
distribution, respectively. The data obtained before 
and after treatment were compared by paired t-test 
(normal) or Wilcoxon (non-normal). Statistical sig-
nificance was set at P , 0.05.
Results
Study population
Forty patients with cervical neoplasia were enrolled 
in  this  study.  Eighteen  (45%)  patients  were  diag-
nosed with pre-invasive neoplasia (CIN group) and 
22  patients  (55%)  were  diagnosed  with  invasive 
neoplasia. The mean age (±SD) of the patients was 
45.2 ± 14.2 yr old, and the CIN group had a lower 
age (39.3 ± 13.8, range of 23–67 yr) than the invasive 
group (50.1 ± 12.9, range of 26–71 yr) (P , 0.05, 
Student t-test). Controls comprised 36 healthy adult 
volunteer women, with a mean age of 42.4 ± 10.2 yr 
(range 26–65 yr).
Patient sera dose-dependently inhibited 
the migration of healthy neutrophils
To investigate the presence of circulating inhibitory 
mediators on neutrophil migration in patients with 
cervical  neoplasia,  control  neutrophils  were  incu-
bated with sera obtained from patients before treat-
ment (n = 5 from each group) and the capacity of the 
neutrophils to migrate toward the chemoattractants 
was assayed. The control group consisted of healthy 
neutrophils treated with normal heterologous serum 
(n = 7). Healthy neutrophils incubated with patient 
sera had a dose-dependent reduction in migration to 
all of the chemoattractants tested and reached statis-
tical significance at a 50% serum concentration for 
fMLP and IL-8 in both groups, compared to 0.5% 
of patient sera (data not shown). Importantly, con-
trol neutrophils incubated with a 50% concentration 
of healthy serum displayed significant migration to 
all chemoattractants compared to the RPMI control, 
whereas the same treatment with patient sera com-
pletely inhibited neutrophil migration to fMLP, LTB4 
and IL-8 (Fig. 1).
Serum cytokine and nitrate concentration
To  investigate  the  systemic  production  of  media-
tors, serum samples were obtained from controls and 
patients with cervical neoplasia at the same time as 
the collection of blood for the migration assay. Serum 
IL-6  and  IL-8  concentrations  were  significantly 
higher  in  cervical  neoplasia  patients  than  in  con-
trols (Fig. 2, panels B and C), whereas TNF-α levels 
approached  the  threshold  of  statistical  significance 
(Fig. 2, panel A). Higher levels of IL-6 and IL-8 were 
also detected in the invasive group compared to con-
trols (Fig. 2, panels B and C).
The  concentrations  (µM)  of  NO  metabolites 
(means ± SD of NO2 + NO3) in serum did not   differ 
between  the  controls  (n  =  29,  26.5  ±  14.5)  and 
patients (n = 22, 28.1 ± 16.2), or between the CIN 
(n = 13, 31.8 ± 17.7) and invasive (n = 9, 25.4 ± 16.2) 
groups.
Production of cytokines and nitrite  
by cultured leukocytes
To estimate the production of inflammatory media-
tors by circulating leukocytes, neutrophil and mono-
nuclear cells obtained from controls and patients with Circulating mediators inhibit the neutrophil migration in cervical neoplasia patients
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cervical  neoplasia  were  cultured  and  the  superna-
tants were collected. The concentrations of TNF-α 
and IL-10 were higher in the neutrophil supernatants 
of patients with invasive cervical neoplasia than the 
controls (panels A and C, P , 0.05). The IL-6 levels 
did not differ between groups (Fig. 3).
The levels of nitrite (means ± SD µM NO2) were 
significantly reduced in neutrophil supernatants from 
patients (n = 11, 6.9 ± 1.1), including both the CIN 
(n = 6, 6.5 ± 1.1) and invasive (n = 5, 7.5 ± 0.7) groups 
compared to controls (n = 7, 10.5 ± 2.1). In opposite, 
higher levels of nitrite were found in the supernatants 
of mononuclear cells from patients (n = 8, 11.1 ± 1.3) 
including the CIN (n = 5, 11.5 ± 1.5) and invasive 
(n  =  3,  10.3  ±  0.5)  groups  compared  to  controls 
(n = 8, 2.6 ± 0.8) (P , 0.01, ANOVA followed by 
Tukey test).
effect of surgical treatment  
on the production of mediators  
and on neutrophil migration
To evaluate the effect of surgical removal of the neo-
plasia on the production of inflammatory mediators 
and on the inhibitory effect of patient sera on neu-
trophil migration, these parameters were re-evaluated 
in  some  of  the  randomized  patients  after  surgery. 
We first assessed if the concentrations of the mediators 
that were elevated in the serum from cervical neopla-
sia patients were altered after surgery.   Figure 4 shows 
that the levels of all of the mediators tested were signif-
icantly reduced after surgery (P , 0.05, paired t-test) 
except for TNF-α (P = 0.052). When tumor stage was 
considered,  the  concentration  of  IL-6  (P  ,  0.05), 
IL-8 (P = 0.076) and NO metabolites (P , 0.05) were 
reduced after surgery in the CIN group, while IL-10 
(P = 0.073) had lower levels after treatment in inva-
sive group (paired t-test).
The concentrations of TNF-α, IL-6, and IL-10 in 
the neutrophil supernatants did not differ between 
patients before and after surgery (n = 6, 3 CIN and 
3 invasive patients). The nitrite levels in the super-
natants  of  neutrophils  and  mononuclear  cells  also 
were  not  different  between  patients  considering 
surgery (n = 6, 3 CIN and 3 invasive patients) (data 
not shown).
We  next  hypothesized  that  a  reduction  in  the 
production  of  soluble  circulating  factors  would  be 
reflected in the restoration of neutrophil migration after 
  treatment. Therefore, we tested the effect of sera, from 
the same five patients from the CIN group that were 
evaluated  at  pretreatment,  on  neutrophil    migration. 
Neutrophils incubated with serum   samples taken after 
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Figure 1. Patient sera, but not normal sera, completely inhibited the migration of control neutrophils. 
notes: The box plots indicate the number of control neutrophils that migrated after incubation in 50% sera from healthy donors (n = 7) or patients with pre-
invasive (n = 5) or invasive (n = 5) cervical neoplasia in response to rPMI (random migration) or to the chemoattractants fMLP, LTB4, and IL-8. The 25th 
and 75th percentiles are represented by a bar centered around the median and the 10th and 90th percentiles are represented by error bars. *P , 0.05 
compared to rPMI, +P , 0.05 compared to the respective chemotactic stimuli from controls (Kruskal-Wallis followed by Dunn).Micheli et al
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surgery  exhibited  significant  migration  towards  all 
the chemoattractants tested and at all serum concen-
trations compared to RPMI (Fig. 5, panel B), while 
migration was reduced when control neutrophils were 
incubated with sera obtained from CIN patients before 
treatment, most evident when 5% and 50% serum con-
centration was used (Fig. 5, panel A).
Discussion
The  present  study  demonstrated  that  circulating 
mediators  impair  neutrophil  function  in  patients 
with uterine cervical neoplasia, apart from the pre-
invasive  stage,  compared  to  healthy  controls. We 
observed a complete failure in the migration of neu-
trophils  treated  with  the  highest  concentration  of 
sera obtained from cervical neoplasia patients at both 
the pre-invasive and invasive stages in response to 
all chemoattractants tested. Important, normal sera 
did not affect neutrophil migration capacity when 
used at the same concentration as the patient sera. 
These data indicate that circulating inhibitory fac-
tors may negatively affect neutrophil migration in 
cervical neoplasia. In agreement with our findings, a 
previous study showed that sera from patients with 
head and neck cancer impaired the function of nor-
mal monocytes.10 Moreover, sera from breast can-
cer  patients  that  had  received  chemotherapy  had 
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Figure  2.  Concentrations  of  TnF-α  (panel  A),  IL-6  (panel  B),  IL-8 
(panel  C),  and  IL-10  (panel  D)  in  serum  samples  from  controls  and 
patients with cervical neoplasia (left bars) and in the pre-invasive and 
invasive groups (right bars) at the time of diagnosis. 
notes: The 25th and 75th percentiles are represented by a bar cen-
tered around the median and the 10th and 90th percentiles are repre-
sented by error bars. The number of subjects is indicated in parentheses. 
  Controls  vs.  patients:  ΛP  =  0.067,  *P  ,  0.05,  **P  ,  0.01  compared   
to controls (Mann-Whitney). Controls vs. stages: *P , 0.05 compared to 
controls (Kruskal-Wallis followed by Dunn).
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Figure 5. Sera obtained from patients with pre-invasive cervical neopla-
sia after surgery restored the migration of control neutrophils. 
notes:  The  box  plots  indicate  the  number  of  emigrated  healthy 
neutrophils, incubated for 30 min in sera (0.5 to 50% concentration) 
of patients with pre-  invasive cervical neoplasia (n = 5), on diagnosis 
(panel A) and 30 to 60 days after surgery (panel B) in response to 
rPMI (random migration) or to the chemoattractants (10−7 M)  fMLP, 
LTB4 and IL-8. The 25th and 75th percentiles are represented by a bar 
centered about the median, the 10th and 90th percentiles are error bars. 
*P , 0.05   compared to the respective rPMI (Kruskal-Wallis   followed 
by Dunn).
a   significant inhibitory effect on the migration of 
healthy neutrophils.11
Neutrophils  express  receptors  necessary  for  the 
recognition and elimination of tumor cells, and are 
rich in granules that contain defensins, proteins with 
high toxic potential against various tumor cells.1 But 
although  activated  neutrophils  perform  antitumor 
activity,17–19 in some tumor types they can promote 
tumor metastasis,20 so, the role of neutrophil in tumor 
microenvironment may change depending on tumor 
type and tumor stage. Our present results support the 
hypothesis that neutrophils may function early in the 
host response against tumor, since patient sera exhib-
ited an inhibitory effect on neutrophil migration apart 
from the pre-invasive stage.
Elevated concentrations of TNF-α, IL-6, IL-8, IL-10, 
and NO are involved in the impairment of neutrophil 
migration in endotoxemia and sepsis.12,21–23 Therefore, 
we investigated the systemic levels of those mediators 
and the specific production by leukocytes. The inhibi-
tory effect of patient sera on the migration of normal 
neutrophils was accompanied by higher serum levels 
of IL-6 and IL-8 in patients with invasive neoplasia. 
A neutrophil migration assay using patient sera pre-
treated with neutralizing antibody to the specific cytok-
ines would help to identify which cytokine(s) mainly 
mediated the inhibition of neutrophil migration.Micheli et al
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Plasma IL-6 levels were elevated in ovarian cancer 
patients at advanced stage compared with tumors of 
low malignity.24 In patients with head and neck carci-
noma, IL-6 serum levels were significantly increased 
compared  to  healthy  controls  and  these  levels 
increased as the tumor stage progressed.25 In breast 
cancer patients, higher concentrations of IL-6, IL-8, 
and  TNF-α  were  detected  compared  to  controls.26 
In patients with ovarian cancer, elevated IL-8 levels 
were associated with poor prognosis.27 Moreover, in 
advanced tumors, the higher serum levels of IL-10 
correlated with poorly differentiated or undifferenti-
ated tumors.28
The serum levels of NO metabolites did not dif-
fer between groups, although previous studies had 
detected elevated NO serum levels in patients with 
cervical  cancer.13,29  However,  failure  to  detect  a 
circulating mediator at a specific time point does 
not rule out the possibility that neutrophil migra-
tion is affected by the factor released at earlier time 
points.
Neutrophils obtained from patients with invasive 
cervical neoplasia produced higher concentrations of 
TNF-α and IL-10 than controls. In agreement, patients 
with advanced cervical cancer had increased levels of 
IL-4 and IL-10 in the supernatants of mononuclear 
cells  compared  to  controls.30  However,  a  differen-
tial production was observed for NO in the patient 
samples  of  leukocyte  supernatants. A  reduction  in 
the nitrite level was detected in neutrophils, while an 
elevation was seen in mononuclear cells compared to 
the controls. A previous study showed that higher lev-
els of nitrite were accompanied by reduced antioxi-
dant activity in the supernatants of leukocytes from 
patients with gastric cancer.31
The tumor microenvironment controls leukocyte 
migration and other functions after these cells arrive 
at the tumor site.32 Considering the higher levels of 
cytokines in sera and in the supernatants of cultured 
leukocytes detected in samples from patients of inva-
sive group compared to controls, it is suggested that 
tumor cells promote an immune response involving 
the production of Th1 and Th2 cytokines. To further 
confirm whether tumor cells could have an effect on 
the production of mediators, and on the inhibitory 
activity of patient sera, we investigated these param-
eters after surgical elimination of the tumor in ran-
domly selected patients.
Neutrophil migration was only assayed in patients 
with  pre-invasive  neoplasia  and  all  of  them  were 
tested before surgery. Significant neutrophil migration 
toward all chemoattractants was observed for con-
trol neutrophils incubated with patient sera obtained 
after  surgery. These  data  strongly  suggest  that  the 
tumor cells produce and/or stimulate the production 
of  inhibitory  mediator(s)  of  neutrophil  migration. 
These  mediators  probably  included  TNF-α,  IL-6, 
IL-8,  IL-10,  and  NO,  since  the  removal  of  tumor 
significantly reduced the production of these factors 
and restored neutrophil migration capacity in the host 
response. The  specific  production  of  mediators  by 
systemic leukocytes was not altered, which supported 
the hypothesis that the tumor cells had a role in the 
production of soluble factors.
In  patients  with  cervical  neoplasia  treated  with 
chemotherapy, a decrease in IL-4 and IL-10 levels 
was observed in responders than non-responders.30 In 
patients with advanced ovarian cancer, serum IL-10 
levels  were  significantly  reduced  within  8  d  after 
  surgery.28  Our  data  suggest  that  no  individual  fac-
tor was responsible for the impairment in neutrophil 
migration, since different mediators were elevated at 
diagnosis and were altered after surgery.
Tumors produce chemokines that recruit   leukocytes. 
However, a deficiency in promoting an inflammatory 
response at locations other than the tumor site exists. 
It  has  been  hypothesized  that  circulating  chemok-
ines may desensitize leukocytes to migrate or that the 
tumor may produce anti-  inflammatory factors.32 Our 
data support the hypothesis that tumor cells produce 
soluble inhibitory factors of neutrophil migration that 
may also affect leukocyte function when present in the 
circulation.
Other factors, which were not evaluated in this 
study, may also have a role in the impairment of leu-
kocyte function in cancer patients. Acute phase pro-
teins, such as alpha-1-acid glycoprotein (AGP) and 
haptoglobin, may have increased production in can-
cer as a reaction to injury.33 It was reported that AGP 
is detected in sera of severely septic patients and is 
able to inhibit neutrophil migration through a NO-
dependent mechanism.23
In  conclusion,  patients  with  cervical  neoplasia 
produce circulating inhibitory mediators of neutro-
phil migration, apart from the pre-invasive stages. 
We presented indirect evidence that those mediators Circulating mediators inhibit the neutrophil migration in cervical neoplasia patients
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could be cytokines and NO. The results also indicate 
that tumor cells act early to impair the innate immune 
response. These findings may contribute to the devel-
opment of new therapeutic strategies in cancer.
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